Americans spend more on healthcare than any other country, largely because the U.S. pays far higher prices for the same surgeries, drugs and medical services. Increased use of costly hospital care and new weight-loss medications has driven spending even higher.

TrumpRx, a new public-private program launched by the Trump administration in partnership with Pfizer, aims to offer direct-to-consumer drug sales at significantly reduced prices. While it seeks to provide discounts on medications, experts suggest it closely resembles existing DTC models like Cost Plus Drugs and may not substantially impact the majority of patients who rely on insurance for prescriptions.